{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T23:52:47Z","timestamp":1725493967234},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T00:00:00Z","timestamp":1408579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["currenttherapeuticres.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.curtheres.2014.08.002","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T10:34:49Z","timestamp":1417775689000},"page":"126-133","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Efficacy and Safety of Celecoxib in Chinese Patients with Ankylosing Spondylitis: A 6-Week Randomized, Double-Blinded Study with 6-Week Open-Label Extension Treatment"],"prefix":"10.1016","volume":"76","author":[{"given":"Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieruo","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.curtheres.2014.08.002_bib1","first-page":"1","article-title":"Seronegative spondylarthropathies","volume":"37","author":"Arnett","year":"1987","journal-title":"Bull Rheum Dis"},{"key":"10.1016\/j.curtheres.2014.08.002_bib2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","article-title":"Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug","volume":"44","author":"Dougados","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.curtheres.2014.08.002_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1590\/S1807-59322011000200012","article-title":"Gender differences in ankylosing spondylitis-associated cumulative healthcare utilization: a population-based cohort study","volume":"66","author":"Chen","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.curtheres.2014.08.002_bib4","first-page":"613","article-title":"Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers","volume":"27","author":"Zink","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib5","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.curtheres.2014.08.002_bib6","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.curtheres.2014.08.002_bib7","first-page":"557","article-title":"Diagnosis and treatment guideline for Ankylosing Spondylitis","volume":"14","year":"2010","journal-title":"Chin J Rheumatol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(94)91843-0","article-title":"Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs","volume":"343","author":"Garcia Rodriguez","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.curtheres.2014.08.002_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00002018-200427050-00003","article-title":"Safety of tumour necrosis factor-alpha antagonists","volume":"27","author":"Khanna","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.curtheres.2014.08.002_bib10","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/bmj.332.7553.1302","article-title":"Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials","volume":"332","author":"Kearney","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.curtheres.2014.08.002_bib11","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","article-title":"Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2","volume":"296","author":"McGettigan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.curtheres.2014.08.002_bib12","doi-asserted-by":"crossref","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","article-title":"Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies","volume":"8","author":"McGettigan","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.curtheres.2014.08.002_bib13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/art.23911","article-title":"Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups","volume":"59","author":"Solomon","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.curtheres.2014.08.002_bib14","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1572-0241.2000.02263.x","article-title":"Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease","volume":"95","author":"Bonner","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0889-857X(05)70042-9","article-title":"Bowel inflammation and the spondyloarthropathies","volume":"24","author":"De Keyser","year":"1998","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.curtheres.2014.08.002_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/gut.40.5.619","article-title":"Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease","volume":"40","author":"Evans","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.curtheres.2014.08.002_bib17","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1572-0241.2000.02262.x","article-title":"Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study","volume":"95","author":"Felder","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/archinte.1992.00400150135025","article-title":"Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature","volume":"152","author":"Gibson","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.curtheres.2014.08.002_bib19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.curtheres.2014.08.002_bib20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2014.08.002_bib21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","article-title":"Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials","volume":"325","author":"Deeks","year":"2002","journal-title":"BMJ"},{"issue":"Suppl 3","key":"10.1016\/j.curtheres.2014.08.002_bib22","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1136\/ard.61.suppl_3.iii40","article-title":"Conventional treatments for ankylosing spondylitis","volume":"61","author":"Dougados","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.curtheres.2014.08.002_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjcard.2006.07.069","article-title":"Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials","volume":"99","author":"White","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib24","first-page":"1805","article-title":"Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis","volume":"33","author":"Barkhuizen","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/ard.2007.075309","article-title":"Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study","volume":"67","author":"Sieper","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.curtheres.2014.08.002_bib26","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","article-title":"Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--a population-based survey","volume":"25","author":"Zochling","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0140-6736(07)60234-7","article-title":"Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison","volume":"369","author":"Laine","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.curtheres.2014.08.002_bib28","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1185\/03007995.2012.717528","article-title":"Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial","volume":"28","author":"Kellner","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.curtheres.2014.08.002_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1056\/NEJM199209103271101","article-title":"Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs","volume":"327","author":"Allison","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.curtheres.2014.08.002_bib30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.gtc.2009.03.007","article-title":"Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications","volume":"38","author":"Lanas","year":"2009","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.curtheres.2014.08.002_bib31","first-page":"1876","article-title":"Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo","volume":"27","author":"Bensen","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib32","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib33","first-page":"35","article-title":"Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis","volume":"20","author":"McKenna","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.curtheres.2014.08.002_bib34","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.curtheres.2014.08.002_bib35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.amjmed.2005.09.054","article-title":"Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study","volume":"119","author":"Singh","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.curtheres.2014.08.002_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0140-6736(10)60673-3","article-title":"Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial","volume":"376","author":"Chan","year":"2010","journal-title":"Lancet"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X14000198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X14000198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T02:22:00Z","timestamp":1538014920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X14000198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":36,"alternative-id":["S0011393X14000198"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2014.08.002","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Celecoxib in Chinese Patients with Ankylosing Spondylitis: A 6-Week Randomized, Double-Blinded Study with 6-Week Open-Label Extension Treatment","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2014.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}